Bart Neyns

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7496017/publications.pdf

Version: 2024-02-01

265 papers	24,371 citations	30551 56 h-index	9118 149 g-index
269 all docs	269 docs citations	269 times ranked	26794 citing authors

#	Article	IF	Citations
1	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. Journal of Clinical Oncology, 2022, 40, 161-170.	0.8	283
2	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. Cancers, 2022, 14, 682.	1.7	6
3	Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights. Current Opinion in Oncology, 2022, 34, 115-122.	1.1	4
4	Anti-PD-1: When to Stop Treatment. Current Oncology Reports, 2022, 24, 905-915.	1.8	5
5	A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. Melanoma Research, 2022, 32, 183-191.	0.6	9
6	Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1+ Myeloid Dendritic Cells. International Journal of Molecular Sciences, 2022, 23, 4865.	1.8	10
7	Computer-aided detection and segmentation of malignant melanoma lesions on whole-body <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si2.svg"><mml:msup><mml:mrow /><mml:mn>18</mml:mn></mml:msup></mml:math>F-FDG PET/CT using an interpretable deep learning approach. Computer Methods and Programs in Biomedicine, 2022, 221, 106902.	2.6	9
8	NivolumabÂplus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Annals of Oncology, 2022, 33, 1052-1060.	0.6	81
9	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology, 2022, 11, .	2.1	54
10	The predictive and prognostic significance of cellâ€free DNA concentration in melanoma. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 387-395.	1.3	17
11	Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls. Acta OncolÂ³gica, 2021, 60, 69-77.	0.8	19
12	Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?. European Journal of Endocrinology, 2021, 184, K1-K5.	1.9	37
13	Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.. Journal of Clinical Oncology, 2021, 39, 58-58.	0.8	19
14	Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse. Cancers, 2021, 13, 442.	1.7	7
15	Therapeutic depletion of CCR8⁺tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. , 2021, 9, e001749.		91
16	Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nature Neuroscience, 2021, 24, 595-610.	7.1	288
17	Choriocapillaris Assessment In Patients Under Mek-Inhibitor Therapy For Cutaneous Melanoma: An Optical Coherence Tomography Angiography Study. Seminars in Ophthalmology, 2021, 36, 1-7.	0.8	2
18	Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. Current Oncology, 2021, 28, 1630-1640.	0.9	4

#	Article	IF	Citations
19	A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT). Cancers, 2021, 13, 2010.	1.7	7
20	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). Cancers, 2021, 13, 2466.	1.7	7
21	A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated BRAF^{V600}/NRAS^{Q61R/K/L} wild-type melanoma (TraMel-WT): Interim efficacy and safety results.. Journal of Clinical Oncology, 2021, 39, 9529-9529.	0.8	2
22	C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. Melanoma Research, 2021, 31, 371-377.	0.6	12
23	Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial. , 2021, 9, e002296.		45
24	Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report. BMC Ophthalmology, 2021, 21, 250.	0.6	9
25	Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy. Melanoma Research, 2021, 31, 272-276.	0.6	3
26	A Solitary Melanoma Metastasis Confined to the Submandibular Gland. Case Reports in Oncology, 2021, 14, 957-962.	0.3	2
27	Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Annals of Oncology, 2021, 32, 917-925.	0.6	76
28	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	1.3	12
29	Characterization and Clinical Utility of BRAFV600 Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma. Cancers, 2021, 13, 3591.	1.7	4
30	SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Annals of Oncology, 2021, 32, S213-S214.	0.6	12
31	The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression. Clinical Lung Cancer, 2021, 22, 432-440.	1.1	16
32	Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study. European Journal of Cancer, 2021, 157, 225-237.	1.3	9
33	A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers, 2021, 13, 168.	1.7	24
34	Antitumor Activity of Ipilimumab or BRAF Â± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006. Annals of Oncology, 2021, , .	0.6	5
35	Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells. Frontiers in Immunology, 2021, 12, 733506.	2.2	4
36	Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study. Supportive Care in Cancer, 2020, 28, 3267-3278.	1.0	31

#	Article	IF	Citations
37	An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma. Melanoma Research, 2020, 30, 524-527.	0.6	5
38	20P Interim safety and efficacy results of a phase II clinical trial on trametinib and low-dose dabrafenib in patients with advanced BRAFV600 wild-type melanoma. Annals of Oncology, 2020, 31, S7.	0.6	0
39	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1435-1448.	0.6	132
40	65MO A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma. Annals of Oncology, 2020, 31, S1443.	0.6	1
41	Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). , 2020, 8, e001146.		35
42	Pembrolizumab for the treatment of uveal melanoma: A case series. Rare Tumors, 2020, 12, 203636132097198.	0.3	8
43	Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. Vaccines, 2020, 8, 670.	2.1	17
44	Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab. Journal of Immunology Research, 2020, 2020, 1-11.	0.9	18
45	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1449-1461.	0.6	69
46	1131P C-reactive protein as biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. Annals of Oncology, 2020, 31, S759.	0.6	1
47	Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1. Case Reports in Oncology, 2020, 13, 1031-1036.	0.3	4
48	TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. , 2020, 8, e000329.		93
49	18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging, 2020, 20, 36.	1.2	46
50	A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunology, Immunotherapy, 2020, 69, 2589-2598.	2.0	44
51	Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.. Journal of Clinical Oncology, 2020, 38, 10013-10013.	0.8	23
52	A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2020, 38, 2534-2534.	0.8	6
53	Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. ELife, 2020, 9, .	2.8	154
54	Automated threshold selection on whole-body 18F-FDG PET/CT for assessing tumor metabolic response. , 2020, , .		0

#	Article	IF	Citations
55	Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases. ESMO Open, 2019, 4, e000464.	2.0	21
56	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncology, The, 2019, 20, 1239-1251.	5.1	812
57	A single arm, open label, phase II, multicenter study to assess the detection of the BRAF V600 mutation on cfDNA from plasma in patients with advanced melanoma. Annals of Oncology, 2019, 30, v544.	0.6	0
58	Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: A matched cohort study. Annals of Oncology, 2019, 30, v668-v669.	0.6	1
59	Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. Journal of Translational Medicine, 2019, 17, 303.	1.8	89
60	Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test. Melanoma Research, 2019, 29, 95-98.	0.6	6
61	Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. Journal of Oncology, 2019, 2019, 1-17.	0.6	55
62	Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 828-835.	0.4	46
63	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
64	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology, 2019, 30, 1154-1161.	0.6	170
65	Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. JCO Precision Oncology, 2019, 3, 1-10.	1.5	25
66	Effectiveness of dabrafenib in the treatment of patients with BRAF V600â€“mutated metastatic melanoma in a Named Patient Program. Melanoma Research, 2019, 29, 527-532.	0.6	6
67	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. European Journal of Cancer, 2019, 107, 175-185.	1.3	13
68	Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma. Melanoma Research, 2019, 29, 85-88.	0.6	15
69	Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma. Cancer Research, 2019, 79, CT188-CT188.	0.4	4
70	GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2019, 37, 2034-2034.	0.8	7
71	Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.. Journal of Clinical Oncology, 2019, 37, 3521-3521.	0.8	12
72	A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).. Journal of Clinical Oncology, 2019, 37, 9585-9585.	0.8	5

#	Article	IF	Citations
73	A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, e14012-e14012.	0.8	1
74	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. Journal of Clinical Oncology, 2019, 37, 635-635.	0.8	31
75	Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. European Journal of Endocrinology, 2019, 181, 363-374.	1.9	154
76	Emotional and cognitive disturbances in long-term melanoma survivors treated with ipilimumab.. Journal of Clinical Oncology, 2019, 37, 97-97.	0.8	0
77	ctDNA as a noninvasive monitoring tool in metastatic melanoma.. Journal of Clinical Oncology, 2019, 37, 9548-9548.	0.8	0
78	Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods. Archives of Pathology and Laboratory Medicine, 2018, 142, 982-991.	1.2	27
79	Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2018, 136, 115-125.	1.4	39
80	Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. Melanoma Research, 2018, 28, 65-70.	0.6	18
81	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigatorâ€™s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, 2018, 36, 383-390.	0.8	431
82	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repairâ€“Deficient/Microsatellite Instabilityâ€“High Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2018, 36, 773-779.	0.8	1,525
83	A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors. Annals of Oncology, 2018, 29, x14.	0.6	3
84	Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab. Annals of Oncology, 2018, 29, x7.	0.6	3
85	Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic. ESMO Open, 2018, 3, e000384.	2.0	1
86	Major determinants of delayed access to innovative medicines for metastatic melanoma: The results of Melanoma World Society and European Association of Dermato-Oncology survey. Annals of Oncology, 2018, 29, viii563.	0.6	0
87	Case Report: Treatment Resistant Ipilimumab Related Colitis in an Elderly Metastatic Melanoma Patient. Journal of Gerontology & Geriatric Research, 2018, 07, .	0.1	0
88	Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Annals of Oncology, 2018, 29, viii714.	0.6	60
89	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. European Journal of Cancer, 2018, 104, 201-209.	1.3	37
90	Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition. Blood Advances, 2018, 2, 2156-2158.	2.5	19

#	Article	IF	Citations
91	Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab. Cancer Medicine, 2018, 7, 4870-4879.	1.3	27
92	4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.. Journal of Clinical Oncology, 2018, 36, 9503-9503.	0.8	71
93	Safety of axitinib plus avelumab in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2018, 36, e14082-e14082.	0.8	3
94	Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.. Journal of Clinical Oncology, 2018, 36, 554-554.	0.8	39
95	Psychosocial outcome and health-related quality of life (HRQoL) in advanced melanoma survivors.. Journal of Clinical Oncology, 2018, 36, 162-162.	0.8	3
96	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of Clinical Oncology, 2017, 35, 226-235.	0.8	458
97	More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. European Journal of Cancer, 2017, 75, 313-322.	1.3	32
98	Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006. European Journal of Cancer, 2017, 72, S128-S129.	1.3	2
99	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncology, The, 2017, 18, 464-472.	5.1	139
100	Open-label, multicentre safety study of vemurafenib inÂ3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European Journal of Cancer, 2017, 79, 176-184.	1.3	31
101	Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006. European Journal of Cancer, 2017, 72, S122-S123.	1.3	14
102	EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL). European Journal of Cancer, 2017, 72, S128.	1.3	3
103	Population Pharmacokinetic Approach Applied to Positron Emission Tomography: Computed Tomography for Tumor Tissue Identification in Patients with Glioma. Clinical Pharmacokinetics, 2017, 56, 953-961.	1.6	1
104	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, The, 2017, 390, 1853-1862.	6.3	1,032
105	Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. ESMO Open, 2017, 2, e000203.	2.0	15
106	Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and <scp>SP</scp>142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system. Histopathology, 2017, 70, 253-263.	1.6	37
107	Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.. Journal of Clinical Oncology, 2017, 35, 3548-3548.	0.8	5
108	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.. Journal of Clinical Oncology, 2017, 35, 9504-9504.	0.8	53

#	Article	IF	Citations
109	Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. Journal of Clinical Oncology, 2017, 35, 9539-9539.	0.8	4
110	Whole-body MRI (WB MRI) including diffusion weighted (DW) imaging for the surveillance of melanoma patients at high risk for recurrence following surgery or systemic therapy.. Journal of Clinical Oncology, 2017, 35, e21072-e21072.	0.8	0
111	Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab.. Journal of Clinical Oncology, 2017, 35, e21030-e21030.	0.8	0
112	Vemurafenibâ€associated <scp>D</scp>upuytrenâ€and Ledderhose palmoplantar fibromatosis in metastatic melanoma patients. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1133-1135.	1.3	4
113	Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. Melanoma Research, 2016, 26, 157-163.	0.6	16
114	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. Journal of Translational Medicine, 2016, 14, 232.	1.8	27
115	Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2016, 128, 147-155.	1.4	40
116	Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion. Cancer Immunology, Immunotherapy, 2016, 65, 727-740.	2.0	33
117	Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4431-4439.	1.8	187
118	More than 5000 patients with metastatic melanoma in Europe per year do not have access to new life-saving drugs. Annals of Oncology, 2016, 27, vi586.	0.6	0
119	COMBI-rechallenge: a phase II clinical trial on dabrafenib plus trametinib in BRAFV600-mutant melanoma patients who previously experienced progression on BRAF(+MEK)-inhibition. Annals of Oncology, 2016, 27, vi389.	0.6	2
120	Estimating the percentage of patients with advanced melanoma achieving long-term survival with pembrolizumab (Pembro) treatment in KEYNOTE-006. Annals of Oncology, 2016, 27, vi382.	0.6	0
121	Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO). Annals of Oncology, 2016, 27, vi386.	0.6	5
122	Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. Journal of Translational Medicine, 2016, 14, 95.	1.8	117
123	Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. Journal of Clinical Oncology, 2016, 34, 1330-1338.	0.8	259
124	Randomized phase II study of axitinib alone or combined with lomustine in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2038-2038.	0.8	1
125	Single-center "real life experience" with pembrolizumab (PEMBRO) in pretreated advanced melanoma patients.. Journal of Clinical Oncology, 2016, 34, e21049-e21049.	0.8	4
126	Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).. Journal of Clinical Oncology, 2016, 34, e21058-e21058.	0.8	0

#	Article	IF	Citations
127	Abstract B003: A randomized controlled phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases. , 2016, , .		0
128	Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. American Journal of Cancer Research, 2016, 6, 2514-2531.	1.4	35
129	Bone Marrow Metastases from a 1p/19q Co-deleted Oligodendroglioma - A Case Report. Anticancer Research, 2016, 36, 4145-9.	0.5	5
130	3328 A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases. European Journal of Cancer, 2015, 51, S673.	1.3	2
131	Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. Melanoma Research, 2015, 25, 550-554.	0.6	39
132	Systemic immune changes associated with adjuvant interferon-Î±2b-therapy in stage III melanoma patients. Melanoma Research, 2015, 25, 357-361.	0.6	13
133	A Case Report of Long-Term Survival following Hepatic Arterial Infusion ofL-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.2	2
134	PD-L1 IHC validation and comparison of E1L3N & SP142 mAbs in melanoma. Annals of Oncology, 2015, 26, viii5.	0.6	2
135	Complete Cytologic Remission of V600E BRAF-Mutant Melanomaâ€“Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib. Journal of Clinical Oncology, 2015, 33, e109-e111.	0.8	31
136	Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. Journal of Neurology, 2015, 262, 742-751.	1.8	10
137	Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. Journal of Translational Medicine, 2015, 13, 9.	1.8	54
138	Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunology, Immunotherapy, 2015, 64, 381-388.	2.0	70
139	Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2015, 372, 2521-2532.	13.9	4,838
140	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 375-384.	5.1	2,353
141	Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. Melanoma Research, 2015, 25, 68-74.	0.6	11
142	Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma. Melanoma Research, 2015, 25, 180-183.	0.6	13
143	Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. OncoImmunology, 2015, 4, e998107.	2.1	65
144	Characterization of thein vivoimmune network of IDO, tryptophan metabolism, PD-L1, andCTLA-4in circulating immune cells in melanoma. OncoImmunology, 2015, 4, e982382.	2.1	95

#	Article	IF	Citations
145	Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. OncoImmunology, 2015, 4, e1019197.	2.1	55
146	Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma. , 2015, , .		2
147	Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma. Anticancer Research, 2015, 35, 5551-7.	0.5	10
148	Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients. Case Reports in Oncological Medicine, 2014, 2014, 1-6.	0.2	35
149	A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy. Annals of Oncology, 2014, 25, v1.	0.6	38
150	O1.05 * AXITINIB, A SELECTIVE VEGFR-1,-2,-3 TYROSINE KINASE INHIBITOR, INHIBITS TUMOR GROWTH AND INCREASES INFILTRATION OF IMMUNE CELLS IN AN INTRACRANIAL MELANOMA MOUSE MODEL. Neuro-Oncology, 2014, 16, ii2-ii2.	0.6	0
151	Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Annals of Oncology, 2014, 25, 2277-2284.	0.6	119
152	Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Journal of Neuro-Oncology, 2014, 117, 141-145.	1.4	52
153	Peritumoral indoleamine 2,3â€dioxygenase expression in melanoma: an early marker of resistance to immune control?. British Journal of Dermatology, 2014, 171, 987-995.	1.4	63
154	Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. Cancer Immunology, Immunotherapy, 2014, 63, 959-967.	2.0	74
155	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncology, The, 2014, 15, 436-444.	5.1	242
156	Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with ipilimumab in patients with pretreated advanced melanoma.. Journal of Clinical Oncology, 2014, 32, 3014-3014.	0.8	4
157	AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells. Oncotarget, 2014, 5, 6801-6815.	0.8	17
158	Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2014, 32, 2018-2018.	0.8	9
159	Loading of dendritic cells for immunotherapy. ISBT Science Series, 2013, 8, 161-164.	1.1	1
160	A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Annals of Oncology, 2013, 24, 2686-2693.	0.6	158
161	Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy. Clinical Cancer Research, 2013, 19, 5292-5299.	3.2	13
162	Characterization of CD8⁺T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL). BioMed Research International, 2013, 2013, 1-8.	0.9	38

#	Article	IF	Citations
163	Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma. Journal of Immunotherapy, 2013, 36, 215-222.	1.2	78
164	Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology, 2013, 31, 3212-3218.	0.8	489
165	Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Annals of Oncology, 2013, 24, 2174-2180.	0.6	150
166	Vemurafenib-induced neutrophilic panniculitis. Melanoma Research, 2012, 22, 399-401.	0.6	46
167	Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Research, 2012, 22, 466-472.	0.6	112
168	Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. International Journal of Oncology, 2012, 41, 1029-1035.	1.4	52
169	Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports. Cancer Investigation, 2012, 30, 712-720.	0.6	10
170	Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4+ and CD8+ T Cells in Melanoma Patients. Molecular Therapy, 2012, 20, 1063-1074.	3.7	85
171	Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. European Journal of Cancer, 2012, 48, 2004-2011.	1.3	92
172	Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. European Journal of Cancer, 2012, 48, 3045-3051.	1.3	51
173	An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals. Journal of Oncology, 2012, 2012, 1-8.	0.6	6
174	Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials. Annals of Oncology, 2012, 23, ix363-ix364.	0.6	12
175	Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. Journal of Immunological Methods, 2012, 377, 23-36.	0.6	24
176	Temozolomide Dosing Regimens for Glioma Patients. Current Neurology and Neuroscience Reports, 2012, 12, 286-293.	2.0	34
177	Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunology, Immunotherapy, 2012, 61, 1033-1043.	2.0	63
178	Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Research, 2012, 32, 1355-9.	0.5	65
179	Cilengitide: an RGD pentapeptide Î±Î½Î²3 and Î±Î½Î²5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncology, 2011, 7, 339-354.	1.1	98
180	Durable Remission of Inoperable Liver Metastasis from Rectal Cancer after Hepatic Arterial Infusion of Oxaliplatin and 5-Fluorouracil in Combination with Intravenous Cetuximab. Current Oncology, 2011, 18, 256-259.	0.9	1

#	Article	IF	Citations
181	Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma. Journal of Immunotherapy, 2011, 34, 448-456.	1.2	124
182	Restoration of tumor equilibrium after immunotherapy for advanced melanoma. Melanoma Research, 2011, 21, 152-159.	0.6	11
183	Phase II study of sunitinib malate in patients with recurrent high-grade glioma. Journal of Neuro-Oncology, 2011, 103, 491-501.	1.4	119
184	18F-FDG PET/CT imaging of an anti-CTLA-4 antibody-associated autoimmune pancolitis. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1390-1391.	3.3	15
185	Anti-CTLA-4 antibody-induced Guillainâ€"BarrÃ© syndrome in a melanoma patient. Annals of Oncology, 2011, 22, 991-993.	0.6	167
186	Phase II study of helical tomotherapy for oligometastatic colorectal cancer. Annals of Oncology, 2011, 22, 362-368.	0.6	27
187	A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV).. Journal of Clinical Oncology, 2011, 29, 2519-2519.	0.8	5
188	CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.. Journal of Clinical Oncology, 2011, 29, TPS134-TPS134.	0.8	1
189	Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. Anticancer Research, 2011, 31, 4457-63.	0.5	26
190	Doseâ€dense temozolomide regimens. Cancer, 2010, 116, 2868-2877.	2.0	89
191	Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2010, 28, 2712-2718.	0.8	389
192	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2010, 28, e696-e697.	0.8	0
193	Small-bowel metastasis of malignant melanoma: video capsule endoscopy appearance. Endoscopy, 2010, 42, E185-E185.	1.0	2
194	Reply to Prakoso et al.. Endoscopy, 2010, 42, 980-980.	1.0	0
195	Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncology, The, 2010, 11, 155-164.	5.1	1,075
196	Immunotherapy of Cancer with Dendritic Cells Loaded with Tumor Antigens and Activated Through mRNA Electroporation. Methods in Molecular Biology, 2010, 629, 403-450.	0.4	24
197	Clinical outcome following therapeutic vaccination with autologous mRNA electroporated dendritic cell (DC) vaccines in patients with advanced melanoma.. Journal of Clinical Oncology, 2010, 28, 8547-8547.	0.8	1
198	The role of cytotoxic drugs in the treatment of central nervous system gliomas. Acta Neurologica Belgica, 2010, 110, 1-14.	0.5	26

#	Article	IF	Citations
199	Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients. Clinical Cancer Research, 2009, 15, 3366-3375.	3.2	149
200	Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Annals of Oncology, 2009, 20, 1596-1603.	0.6	207
201	MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. European Journal of Cancer, 2009, 45, 146-153.	1.3	51
202	Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. World Neurosurgery, 2009, 72, 423-428.	1.3	115
203	Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma. World Neurosurgery, 2009, 72, 518.	1.3	3
204	Primary leptomeningeal anaplastic oligodendroglioma with a 1p36â€“19q13 deletion: Report of a unique case successfully treated with Temozolomide. Journal of the Neurological Sciences, 2009, 287, 267-270.	0.3	28
205	9308 Activity of ipilimumab at 10 mg/kg in patients with advanced melanoma is independent of baseline prognostic factors. European Journal of Cancer, Supplement, 2009, 7, 579.	2.2	5
206	Hemorrhagic regression of melanoma metastases during therapeutic vaccination: a report of three cases. Melanoma Research, 2009, 19, 385-390.	0.6	5
207	Final Overall Results of a Study with a Novel Triplet Induction Chemotherapy Regimen (PACCAGE) Followed by Consolidation Radiotherapy in Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2009, 4, 728-735.	0.5	10
208	Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma. Journal of Clinical Oncology, 2009, 27, 2038-2038.	0.8	22
209	Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. Journal of Clinical Oncology, 2009, 27, 9037-9037.	0.8	21
210	Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated with ipilimumab. Journal of Clinical Oncology, 2009, 27, e20006-e20006.	0.8	9
211	Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in patients with advanced melanoma. Journal of Clinical Oncology, 2009, 27, 9024-9024.	0.8	1
212	Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Annals of Hematology, 2008, 87, 495-496.	0.8	28
213	Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer, 2008, 8, 3.	1.1	58
214	Tolerance of adjuvant letrozole outside of clinical trials. Breast, 2008, 17, 376-381.	0.9	49
215	Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer, 2008, 62, 55-61.	0.9	59
216	A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma. Cancer Investigation, 2008, 26, 269-277.	0.6	39

#	Article	IF	Citations
217	Non-Hodgkin's Lymphoma in Patients With Glioma Treated With Temozolomide. Journal of Clinical Oncology, 2008, 26, 4518-4519.	0.8	29
218	Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells. Journal of Immunology, 2008, 180, 3585-3593.	0.4	86
219	An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Annals of Oncology, 2008, 19, 92-98.	0.6	147
220	Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA. Molecular Therapy, 2008, 16, 1170-1180.	3.7	166
221	Cetuximab Treatment in a Patient with Metastatic Colorectal Cancer and Psoriasis. Current Oncology, 2008, 15, 196-197.	0.9	18
222	A phase II trial of sunitinib in patients with recurrent high-grade glioma. Journal of Clinical Oncology, 2008, 26, 13001-13001.	0.8	12
223	A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma. Journal of Clinical Oncology, 2008, 26, 2017-2017.	0.8	7
224	Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study. Journal of Clinical Oncology, 2008, 26, 9025-9025.	0.8	34
225	Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases. Anticancer Research, 2008, 28, 2459-67.	0.5	12
226	Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. Acta Neurologica Belgica, 2008, 108, 131-4.	0.5	11
227	Techniques for the placement of hepatic artery catheters for regional chemotherapy in unresectable liver metastases. European Journal of Surgical Oncology, 2007, 33, 336-340.	0.5	13
228	Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 1658-1664.	0.8	1,828
229	A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC). Lung Cancer, 2007, 56, 247-254.	0.9	9
230	123I-2-iodo-tyrosine, a new tumour imaging agent: human biodistribution, dosimetry and initial clinical evaluation in glioma patients. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 994-1002.	3.3	9
231	A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer Immunology, Immunotherapy, 2007, 56, 753-759.	2.0	19
232	Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2007, 56, 1513-1537.	2.0	149
233	Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology, 2007, 25, 2000-2000.	0.8	40
234	Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab). Journal of Clinical Oncology, 2007, 25, 4038-4038.	0.8	7

#	Article	IF	Citations
235	Interferon alfa-2b treatment following therapeutic vaccination with mRNA electroporated dendritic cells results in skin depigmentation and tumor regression in patients with advanced melanoma. Journal of Clinical Oncology, 2007, 25, 8537-8537.	0.8	1
236	Comparing immunogenicities of tumor-specific antigens administered as therapeutic vaccines in metastatic melanoma patients. Journal of Clinical Oncology, 2007, 25, 3003-3003.	0.8	0
237	The role of MGMT promotor hypermethylation as a predictive factor for response to temozolomide in recurrent high-grade glioma. Journal of Clinical Oncology, 2007, 25, 12509-12509.	0.8	0
238	Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts). Journal of Clinical Oncology, 2007, 25, 6560-6560.	0.8	1
239	PET and CT demonstration of metastatic invasion of the thoracic duct. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 392-392.	3.3	1
240	Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1. Cancer Immunology, Immunotherapy, 2006, 55, 178-184.	2.0	17
241	A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer, 2006, 6, 285.	1.1	103
242	A cohort pilot study on therapeutic vaccination of advanced melanoma patients with dendritic cells loaded with multiple peptides or electroporated with mRNA. Journal of Clinical Oncology, 2006, 24, 18011-18011.	0.8	1
243	Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. Anticancer Research, 2006, 26, 611-9.	0.5	16
244	P-570 Triplet induction chemotherapy followed by radiotherapy in inoperable stage III non small cell lung cancer (NSCLC). A phase II report. Lung Cancer, 2005, 49, S268.	0.9	0
245	Proto-adjuvant chemotherapy with paclitaxel (P), carboplatin (C) and gemcitabine (G) in locally advanced inoperable non-small cell lung cancer (NSCLC). A phase II study. Journal of Clinical Oncology, 2005, 23, 7285-7285.	0.8	0
246	The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation. Journal of Medical Genetics, 2004, 41, 23e-23.	1.5	54
247	Temozolomide for the Treatment of Recurrent Supratentorial Glioma: Results of a Compassionate use Program in Belgium. Journal of Neuro-Oncology, 2004, 70, 37-48.	1.4	14
248	Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. Journal of Gene Medicine, 2004, 6, 1175-1188.	1.4	63
249	Temozolomide for the treatment of recurrent glioma: Results of a compassionate use program in Belgium. Journal of Clinical Oncology, 2004, 22, 1541-1541.	0.8	2
250	First experience with a new implantable gold marker for extracranial high precision radiotherapy. Journal of Clinical Oncology, 2004, 22, 5144-5144.	0.8	0
251	Neuropathological and molecular aspects of low-grade and high-grade gliomas. Acta Neurologica Belgica, 2004, 104, 148-53.	0.5	18
252	First experience with a new implantable gold marker for extracranial high precision radiotherapy. Journal of Clinical Oncology, 2004, 22, 5144-5144.	0.8	0

#	Article	IF	Citations
253	Restoration of an impaired TGF-beta1 autocrine growth-inhibitory circuit results in growth inhibition of ovarian epithelial cancer cells and complete inhibition of their tumorigenicity. Cancer Detection and Prevention, 2003, 27, 380-388.	2.1	0
254	Loss of nuclear BRCA1 localization in breast carcinoma is age dependent. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 274-279.	1.4	18
255	Pamidronate-Related Nephrotoxicity (Tubulointerstitial Nephritis) in a Patient with Osteolytic Bone Metastases. Nephron, 2001, 89, 467-468.	0.9	27
256	Characterization of Permanent Cell Lines That Contain the AAV2 rep-cap Genes on an Epstein-Barr-Virus-Based Episomal Plasmid. Intervirology, 2001, 44, 255-263.	1.2	2
257	CONTAMINANTS WITHIN BACTERIAL PLASMID PREPARATIONS TRIGGER APOPTOSIS IN LIPOSOME TRANSFECTED OVCAR3, BUT NOT IN SKOV3 OR AZ224 HUMAN OVARIAN CANCER CELLS. Cell Biology International, 2001, 25, 715-723.	1.4	5
258	Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector. British Journal of Cancer, 2001, 85, 1592-1599.	2.9	13
259	Raltitrexed-related Pulmonary Toxicity. Acta OncolÃ³gica, 2000, 39, 537-538.	0.8	2
260	Alteration ofJun proto-oncogene status by plasmid transfection affects growth of human ovarian cancer cells. , 1999, 82, 687-693.		15
261	High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. Journal of Medical Genetics, 1999, 36, 304-8.	1.5	22
262	Insufficient TGF-beta 1 production inactivates the autocrine growth suppressive circuit in human ovarian cancer cell lines. Anticancer Research, 1999, 19, 413-20.	0.5	5
263	Ethical Aspects of Genetic Counseling in Familial Breast and Ovarian Cancer.. Annals of the New York Academy of Sciences, 1997, 833, 170-172.	1.8	2
264	Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium. Oncogene, 1996, 12, 1247-57.	2.6	45
265	Frequent deletion of chromosome 19 and a rare rearrangement of 19p13.3 involving the insulin receptor gene in human ovarian cancer. Oncogene, 1995, 11, 351-8.	2.6	17